Directory of Consumer Driven Services
Program Information
Program Name: Peer to Peer Recovery Education Course
Agency Name: National Alliance on Mental Illness
Year the Program was Started: 1979
Public Contact Person: Kathryn McNulty
Address: 1701 Mission Ave.
Oceanside, CA 92054
Telephone #: 760-722-3754
Email Address:
Website URL:
Program Category: Recovery Education
Target Participants:
African American, Hispanic, Asian/Pacific Islander, Native American/Alaskan, Men, Women, Co-occurring substance abuse, Trauma Survivors, Persons on Inpatient Units, Young Adults, Adults, Older Adults
Program Setting:
Annual Program Budget: Under $10,000
Number of staff: Paid Full-Time: 1-2
Paid Part-Time: 20+
Volunteers: 20+
Consumer involvement in the program
Number of staff members and volunteers who are consumers: All
How often do consumer staff and volunteers participate in program decisions? Sometimes
Number of administrators or board members who are consumers: All
Program Training/ Technical Assistance Materials Available: Training curricula, Program brochure, Guides/Manuals, Website
Cost for materials? No
Program Goals: To increase awareness and effectiveness of consumer recovery
Have any outcomes for this program been assessed through internal or external research? Yes
If Yes, details: You'd need to ask Kathryn McNulty of
Program Mission Statement: Recovery Education, Empowerment, Advocacy
Additional Information: Peer-to-Peer is a unique, experiential learning program for people with any serious mental illness who are interested in establishing and maintaining their wellness and recovery. The course was written by Kathryn McNulty, a person with a psychiatric disability who is also a former provider and manager in the mental health field and a longtime mutual support group member and facilitator. An advisory board comprised of consumer members of NAMI, in consultation with Joyce Burland, Ph.D., author of the successful NAMI Family-to-Family Education Program, helped guide the curriculum's development. In 2005, Peer-to-Peer became supported by AstraZeneca.

Go Back